ArticleCell communication and signaling : CCS2025
The scaffold protein DLG4 facilitates RNF63-mediated ubiquitination and degradation of STAT3 in non-small cell lung cancer.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumor suppressor function of SHMT in a Drosophila RasCell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Disks-large homolog (DLG) family has been found to govern multiple key processes in human cancers. However, their role in non-small cell lung cancer (NSCLC) remains unknown.
methodsThe expression of DLG4 was determined by immunoblotting and q-PCR. The interacting proteins of DLG4 were identified by affinity purification mass spectrometry. The ubiquitination level of STAT3 was verified by denaturation-IP. The protein interactions were determined by co-IP. The clinical significance of DLG4, RNF63, and STAT3 was evaluated by immunohistochemical staining.
resultsIn this study, by evaluating the expression levels of human DLG protein (DLG1-DLG5), we found that DLG4 is significantly downregulated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), two major types of NSCLC. DLG4 overexpression impairs cell proliferation and epithelial-mesenchymal transition migration (EMT) of NSCLC cells. The xenograft model also verifies the inhibitory effects of DLG4 on tumor growth in vivo. Moreover, we determined that DLG4 functions as a novel regulator of STAT3. Mechanistically, DLG4 directly interacts with STAT3 and recruits E3 ubiquitin ligase RNF63 (MKRN3) to STAT3, which promotes STAT3 K48-linked polyubiquitination and proteasome-mediated degradation. Importantly, in human NSCLC specimens, endogenous DLG4 and RNF63 expression levels are inversely correlated with that of STAT3. Moreover, low DLG4 and RNF63 expression correlates with poor patient survival in NSCLC.
conclusionour findings define the role of DLG4 that can diminish NSCLC cell proliferation and tumorigenesis through degrading STAT3 in an RNF63-dependent manner. This work suggests a new treatment strategy against NSCLC caused by aberrant activation of STAT3.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.